Savara

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products.

MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.

Glycologic Limited is a company dedicated to the creation of nutritional, clinical nutrition and drug delivery systems based on carbohydrates which overcome the limitations of other technologies. The Company utilises the properties of carbohydrates to develop customised solutions to a wide variety of nutritional and pharmaceutical problems.

Berkeley Advanced Biomaterials Inc. (BAB) specializes in developing and manufacturing hydroxyapatite (HAP), tricalcium phosphate (TCP), and other calcium-based products. The company's activities are focussed on synthetic bone graft substitutes, sustained-release drug delivery devices, and applications of HAP for protein purification. The company's catalog offers a large variety of products with tailored morphologies and microstructures to match their needs for orthopedic surgery, bone tissue engineering, and life science research. Cem-Ostetic and Bi-Ostetic bone void fillers are approved for sale in the USA and the European Community.

Vascular is driving innovation in vascular access medical technology. The company's passion is uncomplicating venous access, chemotherapy, and drug delivery. The company's product designs offer rapid exchange, Biomimetic coating, power injection ability, and associated improvements that help the company's catheters remain patent and effective. Learn more about how the company's products can improve patient care through reduced complications, while delivering lower overall costs for access and drug delivery.